MK-6837 clinical trials

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

This study is testing a new medicine, MK-6837, by itself and with another drug, pembrolizumab. It's for people with advanced cancers that haven't responded to usual treatments. The main goals are to check its safety and how well people tolerate it.